STL Volume 21 Number 5
3 POSTS 0 COMMENTSPurchase PDF for $2.79
This update covers Pembrolizumab IV injection (Keytruda®), Hyaluronic acid gel filler (Juvéderm Volbella® XC), Biosimilar of infliximab (Flixabi®), Ceftaroline fosamil for IV infusion (Teflaro®), Dermal filler with calcium hydroxylapatite (CaHA) + integral 0.3% lidocaine (Radiesse® + Lidocaine), Ixekizumab SC injection (Talz®), Adapalene gel 0.1% (Differin® Gel), C1 esterase inhibitor(human) for IV infusion (Berinert®)
Sodium Deoxycholate for contouring the jawlines are discussed. With recent approval in Canada (Belkyra™), and the US (Kybella®) for the treatment of submental fat, this is a timely review of this injectable. Clinical trial results, indications, safety and efficacy are discussed.